No Data
No Data
Vigil Neuroscience Plans To Report Data From Phase 1 VG-3927 Trial For AD In Q1 2025; Final Analysis Of IGNITE Phase 2 Iluzanebart Trial For ALSP In Q2 2025; Pursues Accelerated Approval; Strategy Involves Exploring New Neurodegenerative Disease Targets
Vigil Neuroscience Highlights 2024 Corporate Achievements and Upcoming 2025 Milestones
Insider Purchase: President and CEO of $VIGL (VIGL) Buys 5,000 Shares
William Blair Initiates Vigil Neuroscience at Outperform
William Blair Initiates Coverage On Vigil Neuroscience With Outperform Rating
Optimistic Buy Rating for Vigil Neuroscience Amid Market Overreaction